ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Sunday, November 13, 2022

4:30PM-6:00PM: Abstract Number: 1615

Myocardial Infarction in Patients with Systemic Vasculitis and Population Controls: Characteristics and Overall Mortality

Abstracts: Vasculitis – Non-ANCA-Associated and Related Disorders I

4:30PM-6:00PM: Abstract Number: 1612

Prediction of Psoriatic Arthritis Tool (PRESTO): Development and Performance of a New Scoring System for Psoriatic Arthritis Risk

Abstracts: Spondyloarthritis Including PsA – Diagnosis, Manifestations, and Outcomes I: Diagnosis and Disease Activity

4:30PM-6:00PM: Abstract Number: 1620

Probability-based Diagnostic Algorithm in Suspected Giant Cell Arteritis: A Prospective, Multicentre Validity Data from HAS GCA Study

Abstracts: Vasculitis – Non-ANCA-Associated and Related Disorders I

4:30PM-6:00PM: Abstract Number: 1605

Profound Anticoagulant Effects of Initial Antirheumatic Treatments in Early Rheumatoid Arthritis Patients; A NORD-STAR Spin-off Study

Abstracts: RA – Treatment II: Pre- and Early Disease

4:30PM-6:00PM: Abstract Number: 1611

Putative Role of the Histidine and Tryptophan Biochemical Pathways in the Mode of Action of Upadacitinib in Patients with Ankylosing Spondylitis

Abstracts: Spondyloarthritis Including PsA – Diagnosis, Manifestations, and Outcomes I: Diagnosis and Disease Activity

4:30PM-6:00PM: Abstract Number: 1619

Silent Giant Cell Arteritis in Patients with Polymyalgia Rheumatica: Characteristics and Peculiarities

Abstracts: Vasculitis – Non-ANCA-Associated and Related Disorders I

4:30PM-6:00PM: Abstract Number: 1608

Vascular Effect of Treat to Target in Early Rheumatoid Arthritis Patients – A 5-year Prospective Study

Abstracts: RA – Treatment II: Pre- and Early Disease

5:00PM-6:00PM: Abstract Number: 1627

BAFF-var Is a New Predisposing Factor for Primary Sjögren’s Syndrome (pSS) and Impacts Disease Activity

Abstracts: Sjögren's Syndrome – Basic and Clinical Science

5:00PM-6:00PM: Abstract Number: 1624

Blocking IL-1, IL-33 and IL-36 Signaling with the Anti-IL1RAP Antibody mCAN10 Ameliorates Inflammation and Fibrosis in Preclinical Models of Systemic Sclerosis

Abstracts: Systemic Sclerosis and Related Disorders – Basic Science

5:00PM-6:00PM: Abstract Number: 1623

Combined Single-Cell, Bulk RNA Sequencing and Proteomics Analysis Reveals New Candidate Targets Involved in Myocardial Fibrogenesis

Abstracts: Systemic Sclerosis and Related Disorders – Basic Science

5:00PM-6:00PM: Abstract Number: 1621

Genome-wide Association Study in African American Systemic Sclerosis Patients Identifies a Novel Target – Transforming Growth Factor-β3 (TGFβ3)

Abstracts: Systemic Sclerosis and Related Disorders – Basic Science

5:00PM-6:00PM: Abstract Number: 1625

Single Cell and Spatial Transcriptomics Identifies Pathogenic Drivers of Sjogren’s Disease in Humans

Abstracts: Sjögren's Syndrome – Basic and Clinical Science

5:00PM-6:00PM: Abstract Number: 1628

The Sjogren Tool for Assessing Response (STAR): Assessment of Response Rates Overall, According to Baseline Activity and by Domain: Reanalysis of 9 Clinical Trials in Primary Sjogren Syndrome

Abstracts: Sjögren's Syndrome – Basic and Clinical Science

5:00PM-6:00PM: Abstract Number: 1622

TNF Receptor 1 Drives Murine Pulmonary Arterial Hypertension and Is Characterized by Loss of Capillary Endothelial Cells and Pericytes, Smooth Muscle Cell Proliferation, and Alterations in Fibroblast Phenotype

Abstracts: Systemic Sclerosis and Related Disorders – Basic Science

5:00PM-6:00PM: Abstract Number: 1626

Unique Biological Profile of Germinal Centres Within Tertiary Lymphoid Structures in the Salivary Glands of Patients with Sjögren’s Syndrome

Abstracts: Sjögren's Syndrome – Basic and Clinical Science

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].